Drug Profile
NLS 8
Alternative Names: NLS-8Latest Information Update: 11 Oct 2023
Price :
$50
*
At a glance
- Originator NLS Pharma Ltd
- Developer NLS Pharmaceutics Ltd
- Class Neuropsychotherapeutics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease
- Discontinued Attention-deficit hyperactivity disorder
Most Recent Events
- 09 Oct 2023 Discontinued - Preclinical for Attention-deficit hyperactivity disorder in Switzerland (unspecified route) before October 2023 (NLS Pharmaceutics pipeline, October 2023)
- 09 Oct 2023 Preclinical trials in Alzheimer's disease in Switzerland (unspecified route) before October 2023 (NLS Pharmaceutics pipeline, October 2023)
- 28 Jul 2022 No recent reports of development identified for preclinical development in Attention-deficit-hyperactivity-disorder in Switzerland